What is Nucala?

Nucala (mepolizumab) is a biologic therapy medicine used to treat severe eosinophilic asthma that has not responded adequately to asthma medications including high doses of combination medicines such as Advair, Dulera, Symbicort, Breo, and Trelegy.  Nucala is also used for the treatment of nasal polyps which have been non-responsive to other treatments. Nucala is an injectable therapy administered in our office every 4 weeks. 

 

What is Nucala indicated for?

Nucala is indicated for people 6 years of age and older with severe eosinophilic asthma that has not responded to other medications. 

Nucala is also approved for individuals age 18 and older with Nasal polyps. 

Nucala also has indications as a treatment for Eosinophilic Granulomatous with Polyangiitis (EGPA) and Hyper Eosinophilic Syndrome (HES)

 

How does Nucala work?

Eosinophils are a type of white blood cell in the body. Those with eosinophilic asthma have increased levels of eosinophils, which worsens inflammation in their lungs and can cause severe asthma attacks. Nucala reduces eosinophil levels in the blood, which helps prevent asthma attacks, improves breathing and lung function, and better controls asthma symptoms. Taking Nucala may reduce or completely eliminate a patient’s need to take oral steroids daily. Nucala reduces the inflammatory response associated with nasal polyps and nasal polyp symptoms. 

 

Want more information about Nucala?

• Visit the Nucala manufacturer's website

 

Want information about Nucala Patient Assistance Program?

• NUCALA Co-Pay Program